Table 1.
Clinicopathological characteristics of patients in the entire cohort.
| No metastasis | Metastasis | Total | P-Value | |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | ||
| Age, mean (SD), y | 46 (9) | 48 (11) | 47 (10) | 0.542 |
| Tumor size, median (IQR), cm | 2.3 (1.9–2.8) | 3.0 (2.4–3.3) | 3.0 (2.0–3.0) | 0.011 |
| Histological grade | ||||
| I | 3 (25.00) | 1 (3.23) | 4 (9.30) | 0.0523 |
| II | 6 (50.00) | 25 (80.65) | 31 (72.09) | |
| III | 3 (25.00) | 5 (16.13) | 8 (18.60) | |
| Pathological T stage | ||||
| 1 | 6 (50.00) | 7 (22.58) | 13 (30.23) | 0.1729 |
| 2 | 6 (50.00) | 22 (70.97) | 28 (65.12) | |
| 3 | 0 (0.00) | 2 (6.45) | 2 (4.65) | |
| Pathological N stage | ||||
| 0 | 12 (100.00) | 0 (0.00) | 12 (27.91) | < 0.0001 |
| 1 | 0 (0.00) | 16 (51.61) | 16 (37.21) | |
| 2 | 0 (0.00) | 7 (22.58) | 7 (16.28) | |
| 3 | 0 (0.00) | 8 (25.81) | 8 (18.60) | |
| Molecular subtype | ||||
| Luminal A | 2 (16.67) | 7 (22.58) | 9 (20.93) | 0.8696 |
| Luminal B | 2 (16.67) | 7 (22.58) | 9 (20.93) | |
| ERBB2-positive | 5 (41.67) | 9 (29.03) | 14 (32.56) | |
| Triple negative | 3 (25.00) | 8 (25.81) | 11 (25.58) | |
| ER | ||||
| Negative | 5 (41.67) | 13 (41.94) | 18 (41.86) | 1 |
| Positive | 7 (58.33) | 18 (58.06) | 25 (58.14) | |
| PR | ||||
| Negative | 8 (66.67) | 13 (41.94) | 21 (48.84) | 0.2648 |
| Positive | 4 (33.33) | 18 (58.06) | 22 (51.16) | |
| HER2 | ||||
| Negative | 7 (58.33) | 22 (70.97) | 29 (67.44) | 0.667 |
| Positive | 5 (41.67) | 9 (29.03) | 14 (32.56) | |
| Ki-67 | ||||
| ≤ 20 | 3 (25.00) | 8 (25.81) | 11 (25.58) | 1 |
| > 20 | 9 (75.00) | 23 (74.19) | 32 (74.42) | |
| Neoadjuvant | ||||
| Yes | 3 (25.00) | 16 (51.61) | 19 (44.19) | 0.2172 |
| No | 9 (75.00) | 15 (48.39) | 24 (55.81) | |
| Total | 12 | 31 | 43 | |